{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:34:30Z","timestamp":1769175270785,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.anndiagpath.2025.152587","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T07:08:16Z","timestamp":1763276896000},"page":"152587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The diagnostic utility and frequency of CD56 expression in plasma cell myeloma"],"prefix":"10.1016","volume":"81","author":[{"given":"Midori","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoka","family":"Haratake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori Filiz","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rio","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syoma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuha","family":"Tabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.anndiagpath.2025.152587_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2025.152587_bb0010","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","volume":"4th ed","author":"Swerdlow","year":"2017"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152587_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1440-1827.2009.02448.x","article-title":"Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis","volume":"59","author":"Tanaka","year":"2009","journal-title":"Pathol Int"},{"key":"10.1016\/j.anndiagpath.2025.152587_bb0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0002-9440(10)65022-5","article-title":"Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14)","volume":"156","author":"Pruneri","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2025.152587_bb0025","first-page":"47","article-title":"To be or not to be: the role of CD56 in multiple myeloma","volume":"14","author":"Cottini","year":"2023"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152587_bb0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/sajc.sajc_64_17","article-title":"Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: a prospective study","volume":"8","author":"Dass","year":"2019","journal-title":"South Asian J Cancer"},{"issue":"4","key":"10.1016\/j.anndiagpath.2025.152587_bb0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)62556-4","article-title":"Expression of CD56\/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation","volume":"160","author":"Ely","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2025.152587_bb0040","first-page":"61","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90B","author":"Flores-Montero","year":"2016","journal-title":"Int Clin Cyt Soc"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152587_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1309\/AJCPOP7TQ3VHHKPC","article-title":"Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma","volume":"132","author":"Harrington","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152587_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12253-008-9069-1","article-title":"Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses","volume":"15","author":"Ioannou","year":"2009","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"10.1016\/j.anndiagpath.2025.152587_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V76.2.377.377","article-title":"Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)","volume":"76","author":"Van Camp","year":"1990","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.anndiagpath.2025.152587_bb0060","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","article-title":"Redefining CD56 as a biomarker and therapeutic target in multiple myeloma","volume":"20","author":"Cottini","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152587_bb0065","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10068","key":"10.1016\/j.anndiagpath.2025.152587_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152587_bb0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1186\/s12885-024-12880-9","article-title":"Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.anndiagpath.2025.152587_bb0080","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152587_bb0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/leu.2011.373","article-title":"Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.anndiagpath.2025.152587_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153567","article-title":"CD56 expression in multiple myeloma: correlation with poor prognostic markers but no effect on outcome","volume":"225","author":"Koumpis","year":"2021","journal-title":"Pathol Res Pract"},{"issue":"6 Pt 1","key":"10.1016\/j.anndiagpath.2025.152587_bb0095","first-page":"e190","article-title":"Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma","volume":"32","author":"Reid","year":"2010","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152587_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232233","article-title":"CD138-negative plasma cell myeloma: a diagnostic challenge and a unique entity","volume":"12","author":"Setiadi","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"40","key":"10.1016\/j.anndiagpath.2025.152587_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030988","article-title":"Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: a real-world retrospective study","volume":"101","author":"Li","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.anndiagpath.2025.152587_bb0110","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.anndiagpath.2025.152587_bb0115","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.anndiagpath.2025.152587_bb0120","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:53:19Z","timestamp":1769172799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913425001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"alternative-id":["S1092913425001522"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152587","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The diagnostic utility and frequency of CD56 expression in plasma cell myeloma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152587"}}